•Sexual abstinence Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drug. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant. •It is not necessary to use any other method of contraception when complete abstinence is elected. •WOCBP participants who choose complete abs tinence must continue to have pregnancy tests, as specified in Section 2. •Acceptable alternate methods of highly effective contraception must be discussed in the event that the WOCBP participants chooses to forego complete abstinence NOTES: aTypical use failure rates may differ from those when used consistently and correctly. Use should be consistent with local regulations regarding the use of contraceptiv e methods for participants participating in clinical studies. bHormonal contraception may be susceptible to interaction with the st udy drug, which may reduce the efficacy of the contraceptive method. Hormonal contraception is permissible only when there is sufficient evidence that the IMP and other study med ications will not alter hormonal exposures such that contraception would be ineffective or result in increased exposures that could be potentially hazardous. In this case, alternative methods of contraception should be utilized. cIntrauterine devices and intrauteri ne hormone releasing systems are acceptable methods of contraception in the absence of definitive drug interaction studies when horm one exposures from intrauter ine devices do not alter contraception effectiveness Unacceptable Methods of Contraception* •Male condoms (except in setting of azoospermic male participants) or female condom with or without spermicide. Male and female condoms cannot be used simultaneously •Diaphragm with spermicide •Cervical cap with spermicide •Vaginal Sponge with spermicide Revised Protocol No.: 04 Date: 31-May-2019 179 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS •Progestogen-only oral hormonal contraception, wh ere inhibition of ovulation is not the primary mechanism of action •Periodic abstinence (calendar, symp tothermal, post- ovulation methods) •Withdrawal (coitus interruptus). •Spermicide only •Lactation amenorrhea method (LAM) * Local laws and regulations may require use of alternative and/or additional contraception methods.